Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Part of paid clinical trials in Camden, New Jersey.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06593431
Phase
PHASE3
Status
Recruiting

Conditions

  • Oligometastatic
  • Pancreas Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Consolidative Radiation — RADIATION
    Participants will receive treatment through radiation therapy

Study Details

The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).

Key Dates

Start date
Oct 23, 2024
Status verified
May 2026
Primary completion
Jun 29, 2029
Completion
Jun 29, 2029

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MDT (Metastasis-Directed Therapy)
    Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).
  • Experimental: System Therapy (control)
    Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Cooper Hospital University Medical CenterCamdenNew Jersey08103
Megan Mezera, MD
Megan Mezera, MD (PRINCIPAL_INVESTIGATOR)
Cooper Hospital University Medical CenterVoorhees TownshipNew Jersey08043
Megan Mezera, MD
Megan Mezera, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030
Ethan Ludmir, MD
713-825-3169
Ethan Ludmir, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Camden, NJ

Related Studies